Transcatheter aortic valve implantation (TAVI) is a well-established and standard therapy for patients with symptomatic severe aortic stenosis at moderate or high risk for surgical aortic valve replacement. Recently, it has proven non-inferior in patients with low surgical risk. However, due to its high cost, the availability of TAVI is variable worldwide. Our aim was to assess the demographic and clinical characteristics and short-term and long-term outcome of those patients. A medical registry is believed to be an excellent tool to perform a field analysis of patients’ course, documenting short, intermediate, and long-term outcomes. This is the first registry for patients who underwent TAVI in Egypt. Ninety-six patients were included in the study; some were retrospective, and the majority were prospective from 5 different cardiac centers from August 2012 till December 2017. The mean age of patients was 77 years SD ± 7.29; females were 52% of the patients and most of the patients were overweight (BMI 30.74, SD ± 6.83). Sixty-three percent of the patients were frail with Katz index ≤ 5. 3.5% had atrial fibrillation (AF) at presentation. General anesthesia was conducted in only 59.37% of the patients. Transfemoral access was the prevailing route of implantation (90%). The median hospital stay was 4 days. In-hospital and 30 days mortality was only 4.16%. TAVI outcome in Egypt appeared to be very promising with in-hospital complication, and mortality rates being comparable to international registries (4.16% vs. 4.0% in TVT registry) denoting the procedure as safe and beneficial. Establishing a national registry is critical to highlighting strength and weaknesses as well as identifying key areas for improvements.

中文翻译：

---

埃及经导管主动脉瓣注册 (Egy-TVR) 的早期结果

经导管主动脉瓣植入术 (TAVI) 是一种行之有效的标准疗法，适用于有症状的重度主动脉瓣狭窄且具有中等或高度外科主动脉瓣置换术风险的患者。最近，它已被证明在手术风险较低的患者中具有非劣效性。然而，由于成本高昂，TAVI 的可用性在全球范围内各不相同。我们的目的是评估这些患者的人口统计学和临床​​特征以及短期和长期结果。医疗登记被认为是对患者病程进行现场分析、记录短期、中期和长期结果的绝佳工具。这是第一个在埃及接受 TAVI 的患者注册。研究中包括了 96 名患者；有些是回顾性的，大多数是从 2012 年 8 月至 2017 年 12 月来自 5 个不同心脏中心的前瞻性研究。患者的平均年龄为 77 岁 SD ± 7.29；女性占患者的 52%，大多数患者超重（BMI 30.74，SD ± 6.83）。63% 的患者身体虚弱，Katz 指数 ≤ 5。3.5% 的患者在就诊时患有心房颤动 (AF)。只有 59.37% 的患者进行了全身麻醉。经股动脉入路是主要的植入途径（90%）。中位住院时间为 4 天。住院和30天死亡率仅为4.16%。埃及的 TAVI 结果似乎非常有希望，有院内并发症，死亡率与国际登记处相当（4.16% vs. TVT 登记处的 4.0%），表明该程序是安全和有益的。